Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1983 1
1984 1
1985 1
1986 1
1987 2
1988 3
1990 3
1992 2
1993 2
1994 6
1995 14
1996 3
1997 9
1998 11
1999 16
2000 30
2001 9
2002 6
2003 14
2004 8
2005 13
2006 8
2007 11
2008 8
2009 10
2010 13
2011 14
2012 20
2013 9
2014 9
2015 10
2016 9
2017 26
2018 20
2019 24
2020 27
2021 13
Text availability
Article attribute
Article type
Publication date

Search Results

363 results
Results by year
Filters applied: . Clear all
Page 1
Immune-related adverse events of checkpoint inhibitors.
Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suárez-Almazor ME. Ramos-Casals M, et al. Among authors: suarez almazor me. Nat Rev Dis Primers. 2020 May 7;6(1):38. doi: 10.1038/s41572-020-0160-6. Nat Rev Dis Primers. 2020. PMID: 32382051 Review.
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.
Brahmer JR, Lacchetti C, Schneider BJ, Atkins MB, Brassil KJ, Caterino JM, Chau I, Ernstoff MS, Gardner JM, Ginex P, Hallmeyer S, Holter Chakrabarty J, Leighl NB, Mammen JS, McDermott DF, Naing A, Nastoupil LJ, Phillips T, Porter LD, Puzanov I, Reichner CA, Santomasso BD, Seigel C, Spira A, Suarez-Almazor ME, Wang Y, Weber JS, Wolchok JD, Thompson JA; National Comprehensive Cancer Network. Brahmer JR, et al. Among authors: suarez almazor me. J Clin Oncol. 2018 Jun 10;36(17):1714-1768. doi: 10.1200/JCO.2017.77.6385. Epub 2018 Feb 14. J Clin Oncol. 2018. PMID: 29442540 Free PMC article.
Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.
Puzanov I, Diab A, Abdallah K, Bingham CO 3rd, Brogdon C, Dadu R, Hamad L, Kim S, Lacouture ME, LeBoeuf NR, Lenihan D, Onofrei C, Shannon V, Sharma R, Silk AW, Skondra D, Suarez-Almazor ME, Wang Y, Wiley K, Kaufman HL, Ernstoff MS; Society for Immunotherapy of Cancer Toxicity Management Working Group. Puzanov I, et al. Among authors: suarez almazor me. J Immunother Cancer. 2017 Nov 21;5(1):95. doi: 10.1186/s40425-017-0300-z. J Immunother Cancer. 2017. PMID: 29162153 Free PMC article.
Adverse Events in Cancer Immunotherapy.
Abdel-Wahab N, Alshawa A, Suarez-Almazor ME. Abdel-Wahab N, et al. Among authors: suarez almazor me. Adv Exp Med Biol. 2017;995:155-174. doi: 10.1007/978-3-319-53156-4_8. Adv Exp Med Biol. 2017. PMID: 28321817 Review.
Digital Patient Education and Decision Aids.
Lopez-Olivo MA, Suarez-Almazor ME. Lopez-Olivo MA, et al. Among authors: suarez almazor me. Rheum Dis Clin North Am. 2019 May;45(2):245-256. doi: 10.1016/j.rdc.2019.01.001. Epub 2019 Mar 8. Rheum Dis Clin North Am. 2019. PMID: 30952396 Review.
Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.
Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab A. Safa H, et al. Among authors: suarez almazor me. J Immunother Cancer. 2019 Nov 21;7(1):319. doi: 10.1186/s40425-019-0774-y. J Immunother Cancer. 2019. PMID: 31753014 Free PMC article. Review.
International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.
Petty RE, Southwood TR, Manners P, Baum J, Glass DN, Goldenberg J, He X, Maldonado-Cocco J, Orozco-Alcala J, Prieur AM, Suarez-Almazor ME, Woo P; International League of Associations for Rheumatology. Petty RE, et al. Among authors: suarez almazor me. J Rheumatol. 2004 Feb;31(2):390-2. J Rheumatol. 2004. PMID: 14760812 No abstract available.
363 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page